Nang Kuang Pharmaceutical Co., Ltd. has received
final U.S.FDA approval for its ANDA.
Date of events
2022/05/26
To which item it meets
paragraph 51
Statement
1.Date of occurrence of the event:2022/05/26
2.Company name:Nang Kuang Pharmaceutical Co., Ltd.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head Office
4.Reciprocal shareholding ratios:Not Applicable
5.Cause of occurrence:The Abbreviated New Drug Application (ANDA)
for Pemetrexed for Injection indicated for the treatment of lung
cancer has been final approved by the U.S. Food and Drug
Administration (FDA).
6.Countermeasures:The drug will be immediately launched in the
U.S. to increase the revenue.
7.Any other matters that need to be specified:
The ANDA for Pemetrexed for Injection indicated for the treatment of
lung cancer has been reviewed and approved by the FDA.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Nang Kuang Pharmaceutical Co. Ltd. published this content on 26 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 May 2022 11:18:11 UTC.
NANG KUANG PHARMACEUTICAL CO., LTD. is principally engaged in the manufacture, processing and trading of western medicine. The company main products include injections, sterile injections, powder injections, hard capsules, bare ingots, film ingots, casing ingots, granules and creams, among others. The Company is also engaged in the manufacture, processing and trading of medical equipment. The Company distributes its products within the domestic market and to overseas markets.
NANG KUANG PHARMACEUTICAL CO., LTD. 
